JAC Advance Access published online on March 16, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki079
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Weg door Jonkerbos 100, 6532 sz Nijmegen, The Netherlands
* To whom correspondence should be addressed. Interest in the relationships between the pharmacokinetics (PK) and pharmacodynamics (PD) of antimicrobial agents has increased over recent years. Since the appearance 2 years ago of our first article describing terminology in PK/PD, the field has continued to expand rapidly, urgently requiring an update. This paper describes in a uniform manner the use of PK/PD expressions for antimicrobial agents, and their units.
Leading article
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update
2 Diversa Corp., San Diego, CA, USA
3 Department of Infectious Diseases, Uppsala University Hospital, Uppsala, Sweden
4 Department of Pharmaceutics, University of Florida, Gainesville, FL, USA
5 Ordway Research Institute, Albany, New York, NY, USA
Johan W. Mouton, E-mail: Mouton{at}cwz.nl
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. van Gennip, C. Moser, L. D. Christensen, T. Bjarnsholt, H. Calum, P. O. Jensen, L. Christophersen, H. P. Hougen, O. Ciofu, S. Molin, et al. Augmented effect of early antibiotic treatment in mice with experimental lung infections due to sequentially adapted mucoid strains of Pseudomonas aeruginosa J. Antimicrob. Chemother., December 1, 2009; 64(6): 1241 - 1250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schmidt, S. N. Sabarinath, A. Barbour, D. Abbanat, P. Manitpisitkul, S. Sha, and H. Derendorf Pharmacokinetic-Pharmacodynamic Modeling of the In Vitro Activities of Oxazolidinone Antimicrobial Agents against Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., December 1, 2009; 53(12): 5039 - 5045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-S. Kesteman, A. A. Ferran, A. Perrin-Guyomard, M. Laurentie, P. Sanders, P.-L. Toutain, and A. Bousquet-Melou Influence of Inoculum Size and Marbofloxacin Plasma Exposure on the Amplification of Resistant Subpopulations of Klebsiella pneumoniae in a Rat Lung Infection Model Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4740 - 4748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Lounis, T. Gevers, J. Van Den Berg, L. Vranckx, and K. Andries ATP Synthase Inhibition of Mycobacterium avium Is Not Bactericidal Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4927 - 4929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Brinch, A. Sandberg, P. Baudoux, F. Van Bambeke, P. M. Tulkens, N. Frimodt-Moller, N. Hoiby, and H.-H. Kristensen Plectasin Shows Intracellular Activity against Staphylococcus aureus in Human THP-1 Monocytes and in a Mouse Peritonitis Model Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4801 - 4808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M Shea, S C. Cheatham, D. W Smith, M. F Wack, K. M Sowinski, and M. B Kays Comparative Pharmacodynamics of Intermittent and Prolonged Infusions of Piperacillin/Tazobactam Using Monte Carlo Simulations and Steady-State Pharmacokinetic Data from Hospitalized Patients Ann. Pharmacother., November 1, 2009; 43(11): 1747 - 1754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Zhanel, P. J. Baudry, F. Tailor, L. Cox, D. J. Hoban, and J. A. Karlowsky Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum {beta}-lactamases, AmpC {beta}-lactamases and reduced susceptibility to carbapenems using an in vitro model J. Antimicrob. Chemother., October 1, 2009; 64(4): 824 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ikawa, K. Nomura, N. Morikawa, K. Ikeda, and M. Taniwaki Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections J. Antimicrob. Chemother., October 1, 2009; 64(4): 840 - 844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Zhanel, D. Voth, K. Nichol, J. A. Karlowsky, A. M. Noreddin, and D. J. Hoban Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model J. Antimicrob. Chemother., August 1, 2009; 64(2): 364 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Bulitta, C. B. Landersdorfer, M. Kinzig, U. Holzgrabe, and F. Sorgel New Semiphysiological Absorption Model To Assess the Pharmacodynamic Profile of Cefuroxime Axetil Using Nonparametric and Parametric Population Pharmacokinetics Antimicrob. Agents Chemother., August 1, 2009; 53(8): 3462 - 3471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Roberts, C. M. J. Kirkpatrick, M. S. Roberts, T. A. Robertson, A. J. Dalley, and J. Lipman Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution J. Antimicrob. Chemother., July 1, 2009; 64(1): 142 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Landersdorfer, M. Kinzig, J. B. Bulitta, F. F. Hennig, U. Holzgrabe, F. Sorgel, and J. Gusinde Bone Penetration of Amoxicillin and Clavulanic Acid Evaluated by Population Pharmacokinetics and Monte Carlo Simulation Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2569 - 2578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Schmidt, K. Rock, M. Sahre, O. Burkhardt, M. Brunner, M. T. Lobmeyer, and H. Derendorf Effect of Protein Binding on the Pharmacological Activity of Highly Bound Antibiotics Antimicrob. Agents Chemother., November 1, 2008; 52(11): 3994 - 4000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-B. Michel, P. J. Yeh, R. Chait, R. C. Moellering Jr., and R. Kishony Drug interactions modulate the potential for evolution of resistance PNAS, September 30, 2008; 105(39): 14918 - 14923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. De Jongh, R. Hens, V. Basma, J. W. Mouton, P. M. Tulkens, and S. Carryn Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection J. Antimicrob. Chemother., February 1, 2008; 61(2): 382 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ikawa, N. Morikawa, N. Urakawa, K. Ikeda, H. Ohge, and T. Sueda Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients J. Antimicrob. Chemother., December 1, 2007; 60(6): 1395 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-L. Toutain, A. Bousquet-Melou, and M. Martinez AUC/MIC: a PK/PD index for antibiotics with a time dimension or simply a dimensionless scoring factor? J. Antimicrob. Chemother., December 1, 2007; 60(6): 1185 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Mouton, N. Punt, and A. A. Vinks Concentration-Effect Relationship of Ceftazidime Explains Why the Time above the MIC Is 40 Percent for a Static Effect In Vivo Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3449 - 3451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Odenholt, E. Lowdin, and O. Cars Pharmacodynamic Effects of Telavancin against Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Strains in the Presence of Human Albumin or Serum and in an In Vitro Kinetic Model Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3311 - 3316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Plasencia, N. Borrell, M. D. Macia, B. Moya, J. L. Perez, and A. Oliver Influence of High Mutation Rates on the Mechanisms and Dynamics of In Vitro and In Vivo Resistance Development to Single or Combined Antipseudomonal Agents Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2574 - 2581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Bulitta, S. B. Duffull, M. Kinzig-Schippers, U. Holzgrabe, U. Stephan, G. L. Drusano, and F. Sorgel Systematic Comparison of the Population Pharmacokinetics and Pharmacodynamics of Piperacillin in Cystic Fibrosis Patients and Healthy Volunteers Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2497 - 2507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Zhanel, S. Derkatch, N. Laing, A. M. Noreddin, and D. J. Hoban Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model J. Antimicrob. Chemother., January 1, 2007; 59(1): 144 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Roos, J. Bulitta, J. Lipman, and C. M. J. Kirkpatrick Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units J. Antimicrob. Chemother., November 1, 2006; 58(5): 987 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Haritova, N. V. Rusenova, P. R. Parvanov, L. D. Lashev, and J. Fink-Gremmels Integration of Pharmacokinetic and Pharmacodynamic Indices of Marbofloxacin in Turkeys Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3779 - 3785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. E. Wagenlehner, M. Kinzig-Schippers, U. Tischmeyer, C. Wagenlehner, F. Sorgel, and K. G. Naber Urinary Bactericidal Activity of Extended-Release Ciprofloxacin (1,000 Milligrams) versus Levofloxacin (500 Milligrams) in Healthy Volunteers Receiving a Single Oral Dose Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3947 - 3949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. J. M. Bakker-Woudenberg, M. T. ten Kate, W. H. F. Goessens, and J. W. Mouton Effect of Treatment Duration on Pharmacokinetic/Pharmacodynamic Indices Correlating with Therapeutic Efficacy of Ceftazidime in Experimental Klebsiella pneumoniae Lung Infection. Antimicrob. Agents Chemother., September 1, 2006; 50(9): 2919 - 2925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Buerger, N. Plock, P. Dehghanyar, C. Joukhadar, and C. Kloft Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2455 - 2463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Giannoni, P. Moreillon, J. Cotting, A. Moessinger, J. Bille, L. Decosterd, G. Zanetti, P. Majcherczyk, and D. Bugnon Prospective determination of plasma imipenem concentrations in critically ill children. Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2563 - 2568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Zhanel, J. James, S. Derkatch, N. Laing, A. M. Noreddin, and D. J. Hoban Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae J. Antimicrob. Chemother., July 1, 2006; 58(1): 112 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Macia, N. Borrell, M. Segura, C. Gomez, J. L. Perez, and A. Oliver Efficacy and Potential for Resistance Selection of Antipseudomonal Treatments in a Mouse Model of Lung Infection by Hypermutable Pseudomonas aeruginosa Antimicrob. Agents Chemother., March 1, 2006; 50(3): 975 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Burgess and C. R. Frei Comparison of {beta}-lactam regimens for the treatment of Gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics J. Antimicrob. Chemother., November 1, 2005; 56(5): 893 - 898. [Abstract] [Full Text] [PDF]
|
|